CUE Earnings & Financial Statements
Cue Biopharma, Inc.
$18.60
-$0.97(-4.96%)
51
Overall
60
Value
30
Tech
65
Quality
Market Cap
$135.12M
Volume
244.96K
52W Range
$4.97 - $45.50
Target Price
$81.02
CUE earnings and financial statements: Cue Biopharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CUE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M |
| Operating income | -$26.55M | -$41.50M | -$52.15M | -$53.78M | -$43.71M |
| EBITDA | $333.0K | -$392.0K | -$49.13M | -$50.49M | -$43.67M |
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | -$44.16M |
| EPS (diluted) | $-0.28 | $-21.60 | $-33.30 | $-44.70 | $-42.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $42.21M | $32.19M | $61.53M | $91.28M | $83.40M |
| Total liabilities | $15.78M | $14.69M | $24.45M | $25.60M | $17.91M |
| Shareholders’ equity | $26.43M | $17.50M | $37.09M | $65.68M | $65.49M |
| Cash and equivalents | $27.14M | $22.46M | $48.51M | $51.61M | $64.37M |
| Long-term debt | $2.29M | $1.00M | $7.36M | $14.05M | $5.12M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | -$38.84M |
| Capital expenditure | -$137.0K | $32.0K | $2.0K | -$171.0K | -$913.0K |
| Free cash flow | -$21.86M | -$36.40M | -$39.96M | -$41.98M | -$39.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CUE | $18.60 | -5.0% | 244.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |